StartX Med COVID-19 Task Force companies continue to announce new developments, including advancements towards a cure. Several companies are working on new drugs to treat COVID-19, including the most common lung disease caused by it, Acute Respiratory Distress Syndrome (ARDS), and are accelerating their efforts to take their treatments into clinical settings. Please let us know if you would like introductions to these StartX Med therapeutics companies working on COVID-19 treatments: GEn1E Lifesciences Inc., Guided Clarity Inc., Globavir Biosciences Inc., AP Stem, and Synova Life Sciences.
A number of companies are also coordinating with city, county and state officials and healthcare systems to offer solutions free of charge during the pandemic.
The StartX Med COVID-19 Task Force was formed at the onset of the pandemic with a mission to deliver solutions for the prevention, diagnostics and treatment of the novel coronavirus. The Task Force now consists of nearly 100 Stanford alumni scientists, physicians and engineers focused on supporting government officials, healthcare systems, and communities in the fight against COVID-19. See full press release.
Enable Biosciences - Call to Action: Good Tests for Coronavirus are Essential - Help Us Validate
Sandstone Diagnostics - Sandstone Submits Torq™ ZDisc for FDA Clearance
KangarooHealth - KangarooHealth Launches Solutions for COVID-19 Monitoring
StartX is a nonprofit organization advancing the development of Stanford’s top entrepreneurs through experiential education, access to thousands of VCs and investors, and a Who’s Who of industry leaders and serial entrepreneurs providing mentorship. The founder community consists of a diverse mix of 1500+ well-funded Growth-Stage Founders, tenured Stanford Professor Founders, and highly-successful Stanford Alumni Founders. Collectively, StartX companies have raised $8 billion in funding with a combined valuation of more than $25 billion to date. StartX’s Corporate Innovation program helps global corporations quickly test market-ready technology from Stanford alumni founders through structured co-creation and pilot programs. Ranked as a number one accelerator nationally by MIT’s Seed Accelerator Rankings Project, StartX venture funded companies have a 92% survival and acquisition rate in a wide range of industries from consumer Internet and retail products to enterprise software, biotechnology and medical devices.
StartX and StartX Med, the medical entrepreneurial vertical of StartX, includes accomplished founders ranging from undergraduates and masters students to post docs, professors and Stanford alumni being mentored by top Silicon Valley industry leaders. For medical tech founders homegrown at Stanford’s School of Medicine, having intimate access to domain experts and care environments has been fundamental to their success. StartX Med entrepreneurial scientists are changing the world with medical breakthroughs and successful life-saving research trials, including an average of more than six FDA approvals per year. Clinical partners of StartX Med companies encompass more than 250 hospitals, 30,000 care centers, 50,000 physicians and 65 million annual patient visits. StartX Med founders also have the opportunity to utilize 2,000 square feet of shared wet lab space at the StartX facility, located down the street from Stanford University.
StartX continues to be a unique startup community compared to accelerators and incubators and does not take equity in companies for admittance into its programs. For information on the StartX Med COVID-19 Task Force or how you can help, please send inquiries to: COVID19TF@StartX.com